ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc (ABOS)

2.82
0.00
(0.00%)
Closed July 15 4:00PM
0.00
0.00
(0.00%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
2.82
Bid
2.68
Ask
2.83
Volume
-
0.00 Day's Range 0.00
1.8101 52 Week Range 11.3099
Market Cap
Previous Close
2.82
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
399,909
Shares Outstanding
60,079,778
Dividend Yield
-
PE Ratio
-3.24
Earnings Per Share (EPS)
-0.87
Revenue
-
Net Profit
-52.37M

About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets... Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Acumen Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ABOS. The last closing price for Acumen Pharmaceuticals was $2.82. Over the last year, Acumen Pharmaceuticals shares have traded in a share price range of $ 1.8101 to $ 11.3099.

Acumen Pharmaceuticals currently has 60,079,778 shares outstanding. The market capitalization of Acumen Pharmaceuticals is $169.42 million. Acumen Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.24.

ABOS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.521.55172413792.322.982.2554854042.5859682CS
40.176.415094339622.652.982.087288842.39781148CS
12-0.39-12.14953271033.213.922.083999092.67622464CS
26-1-26.17801047123.825.092.083745893.22610926CS
52-8.21-74.433363553911.0311.30991.81015973155.27441949CS
156-15.53-84.632152588618.3520.291.81014212266.89626554CS
260-22.25-88.751495811725.0726.981.81014199927.01023097CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0

ABOS Discussion

View Posts
Monksdream Monksdream 2 months ago
ABOS under $5
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
ABOS 10Q due 3/26
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
ABOS new 52 week low
๐Ÿ‘๏ธ0
prof81 prof81 11 months ago
Buying pressureโ€ฆโ€ฆ
๐Ÿ‘๏ธ0
bayjammng bayjammng 12 months ago
Could someone please ask the company how they compare to those in today's CNN article - thx. https://www.cnn.com/2023/07/17/health/second-alzheimers-drug-to-slow-disease-may-be-approved-this-year/index.html
๐Ÿ‘๏ธ0
bayjammng bayjammng 12 months ago
Could someone please ask the company how they compare to those in today's CNN article - thx. https://www.cnn.com/2023/07/17/health/second-alzheimers-drug-to-slow-disease-may-be-approved-this-year/index.html
๐Ÿ‘๏ธ0
Stockexpertpro Stockexpertpro 12 months ago
Ouch Stock Offering With Warrants
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 12 months ago
wow went even higher
๐Ÿ‘๏ธ0
Jayzp Jayzp 12 months ago
THER STOCK..WILL JUMP SAME WAY as abos, prfx

THER CANCER TESTS AND TREATMENT OPTIONS

THERALINK.COM

Going to be nasdaq merger with BACK
๐Ÿ‘๏ธ0
Stockexpertpro Stockexpertpro 12 months ago
ABOS Nice Watch BBIO Above 31$ on News as well
๐Ÿ‘๏ธ0
tw0122 tw0122 12 months ago
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimerโ€™s Disease at the Alzheimerโ€™s Association International Conference (AAIC) 2023

Source: GlobeNewswire Inc.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AรŸOs) for the treatment of Alzheimerโ€™s disease (AD), today presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AรŸO targeting antibody therapy in early AD, at the Alzheimerโ€™s Association International Conference (AAIC®) 2023, taking place in Amsterdam and online from July 16-20, 2023.
Topline results demonstrated that ACU193 was generally well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1, first-in-human, randomized, double-blind, placebo-controlled study in both single and multiple doses in 60 participants with early AD. Dose levels were 2, 10, 25 and 60 mg/kg for one to three doses administered intravenously. An analysis of change in amyloid plaque load, as measured by positron emission tomography (PET) SUVr, demonstrated a rapid, dose-related mean decrease at the higher dose levels studied (60 mg/kg every 4 weeks [Q4W] and 25 mg/kg every 2 weeks [Q2W]). This finding is comparable to mean amyloid plaque decreases of approved Aß monoclonal antibodies at similar time points in their clinical development. The overall rate of amyloid related imaging abnormalities โ€“ edema (ARIA-E) was 10.4%, which included one case of symptomatic ARIA-E (2.1%). Pharmacokinetic results in serum and cerebrospinal fluid (CSF) demonstrated statistically significant dose proportionality and support monthly dosing of ACU193. Statistically significant, dose-related central target engagement was observed as measured by ACU193-AßO complex, establishing the first target engagement assay developed that is specific to an AßO-targeting antibody. An exposure response relationship (Emax) model revealed near maximal target engagement with repeated dosing at 25 mg/kg and 60 mg/kg.

โ€œWe are very pleased to present the first clinical data from our Phase 1 INTERCEPT-AD study at AAIC. ACU193โ€™s observed dose-related central target engagement, rapid reduction of amyloid plaque and compelling safety profile validate our confidence in ACU193โ€™s differentiated mechanism of action: selectively targeting amyloid beta oligomers,โ€ said Daniel Oโ€™Connell, President and Chief Executive Officer of Acumen. โ€œWe believe that the robust data package generated by this comprehensive Phase 1 study establishes ACU193โ€™s broad therapeutic index and guides a future clinical dosing rationale. We look forward to an anticipated interaction with the FDA in the fourth quarter to inform our next phase of development for ACU193.โ€

ACU193 Demonstrated Rapid, Dose-Related, Statistically Significant Amyloid Plaque Reduction
Higher doses of ACU193 (60 mg/kg Q4W and 25 mg/kg Q2W) showed a statistically significant reduction in amyloid plaque load as determined by amyloid PET after 6-12 weeks (from baseline to endpoint within cohorts (p = 0.01)). This finding provides evidence that ACU193 is active in the brain.

Mean Reduction in Amyloid Plaque (Centiloids)
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 12 months ago
ABOS: Could get a little pop behind this news:
https://www.globenewswire.com/news-release/2023/07/16/2705282/0/en/Acumen-Pharmaceuticals-Presents-Positive-Topline-Results-from-First-in-Human-Phase-1-Study-of-ACU193-for-Early-Alzheimer-s-Disease-at-the-Alzheimer-s-Association-International-Conf.html
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
Down over 50% from yearly highs and still dropping. Back to 3's I guess.
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
One penny away haha. That's amazing. Charts never lie.
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
Almost there.
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
Getting close to my buy price. 6s probably today
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
I'm a buyer under $7. Just going by the charts and support is at $6.50 ish range. GL.
๐Ÿ‘๏ธ0
starkd748 starkd748 2 years ago
I never look at YouTube or analysts ELLIOTT WAVES and fibonanci..If the .618 holds at 7.95 would be bullish for wave 5 on the ELLIOTT WAVE either that or it goes to the fibonanci .382 level in the 6s
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
I know TA. I was just pointing out that these people were pumping it at the peak with a buy rating. That's like a you tuber telling you about a penny stock after it ran up 200% that day. The fibs havnt been very predictable lately in this bear market. But for a short term bounce maybe the .618 is a good indicator. I'm looking at the chart and there is some support at around the $7.00 level and a lot of support at the $6.50ish level. Anything under $8 does seem like a good time to start dollar cost averaging back in however in my opinion. GL. $ABOS
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
I know TA. I was just pointing out that these people were pumping it at the peak with a buy rating. That's like a you tuber telling you about a penny stock after it ran up 200% that day. The fibs havnt been very predictable lately in this bear market. But for a short term bounce maybe the .618 is a good indicator. I'm looking at the chart and there is some support at around the $7.00 level and a lot of support at the $6.50ish level. Anything under $8 does seem like a good time to start dollar cost averaging back in however in my opinion. GL. $ABOS
๐Ÿ‘๏ธ0
starkd748 starkd748 2 years ago
7.95 at the .618 is a buy if the pivot point holds we go to the 1.618 fibonanci extension...Analysts don't mean anything...Chart the fibonanci retracement...You need newbies need to understand technical analysis not reading prs lmfao...
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
So how much did they pay these analysts to give it a buy a raiting? Back to $5?
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Closed @ $10 :)
๐Ÿ‘๏ธ0
starkd748 starkd748 2 years ago
Me too I'm waiting next week lol
๐Ÿ‘๏ธ0
Moonboy1 Moonboy1 2 years ago
Where's the gap? I can't get my bar chart up on trading view.
๐Ÿ‘๏ธ0
Imott Imott 2 years ago
I would like the share price to get to 7.65 around 355 PM today. That may not happen as I could be a dollar short.
๐Ÿ‘๏ธ0
starkd748 starkd748 2 years ago
Gap fill time stochastic overbought
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Yes!
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
broke to the UPside nicely today
๐Ÿ‘๏ธ0
starkd748 starkd748 2 years ago
Waiting on the gap to fill then I buy for a flip...Gaps always get filled
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
the open shook some out, then it took off aGAIN

CONGRAT$ to anyone making $$
๐Ÿ‘๏ธ0
Pt3 Pt3 2 years ago
Pick me up 9
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Alzheimerโ€™s drug Rally
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock